Neoadjuvant Targeted Molecular Therapy Before Renal Surgery

摘要: Abstract Neoadjuvant targeted molecular therapy may benefit select patients with metastatic renal cell carcinoma. The primary use of this in disease is to reduce tumor burden, prevent distant metastasis, and increase overall survival. size complexity, facilitate partial nephrectomy rather than radical nephrectomy, downstage thrombus facilitating thrombectomy, make unresectable tumors resectable when applied selected patients. These potential benefits neoadjuvant require further clinical trials better define the function oncological survival outcomes receiving each active agent.